Cargando…

SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein()

Nucleophosmin-anaplastic lymphoma kinase–expressing (NPM-ALK(+)) T-cell lymphoma is an aggressive form of cancer that commonly affects children and adolescents. The expression of NPM-ALK chimeric oncogene results from the chromosomal translocation t(2;5)(p23;q35) that causes the fusion of the ALK an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vishwamitra, Deeksha, Curry, Choladda V., Shi, Ping, Alkan, Serhan, Amin, Hesham M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611074/ https://www.ncbi.nlm.nih.gov/pubmed/26476082 http://dx.doi.org/10.1016/j.neo.2015.09.005

Ejemplares similares

The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma
por: Vishwamitra, Deeksha, et al.
Publicado: (2015)

TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK (+) T‐cell lymphoma
por: Shi, Wenyu, et al.
Publicado: (2017)

The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
por: George, Suraj Konnath, et al.
Publicado: (2014)

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2019)

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
por: Lobello, Cosimo, et al.
Publicado: (2018)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2023)

NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases
por: Pearson, Joel D., et al.
Publicado: (2012)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

Type I insulin-like growth factor receptor signaling in hematological malignancies
por: Vishwamitra, Deeksha, et al.
Publicado: (2016)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Inhibition of Rac controls NPM–ALK-dependent lymphoma development and dissemination
por: Colomba, A, et al.
Publicado: (2011)

NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
por: Andraos, Elissa, et al.
Publicado: (2021)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
por: Haque, Moinul, et al.
Publicado: (2019)

ALK Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature
por: Shekar, Meghan, et al.
Publicado: (2023)

EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML
por: Skayneh, Hala, et al.
Publicado: (2022)

Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK–driven lymphomagenesis
por: Redl, Elisa, et al.
Publicado: (2020)

Posttranslational modification and microtubule stability
Publicado: (1987)

Functional characterization of NPM1–TYK2 fusion oncogene
por: Kuravi, Sudhakiranmayi, et al.
Publicado: (2022)

Atractylodin Inhibits Interleukin-6 by Blocking NPM-ALK Activation and MAPKs in HMC-1
por: Chae, Hee-Sung, et al.
Publicado: (2016)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma
por: Krumbholz, Manuela, et al.
Publicado: (2018)

Proteomic Phosphosite Analysis Identified Crucial NPM-ALK-Mediated NIPA Serine and Threonine Residues
por: Gengenbacher, Anina, et al.
Publicado: (2019)

Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK
por: Uchihara, Yuki, et al.
Publicado: (2017)

Emergence and Enhancement of Ultrasensitivity through Posttranslational Modulation of Protein Stability
por: Kumbale, Carla M., et al.
Publicado: (2021)

De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells
por: Babin, Loélia, et al.
Publicado: (2022)

The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein
por: Pearson, Joel D, et al.
Publicado: (2012)

Human Oncogenic Herpesvirus and Post-translational Modifications – Phosphorylation and SUMOylation
por: Chang, Pei-Ching, et al.
Publicado: (2016)

CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas
por: Kuravi, Sudhakiranmayi, et al.
Publicado: (2019)

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
por: Cappelli, Luca Vincenzo, et al.
Publicado: (2021)

Posttranslational Chemical Mutagenesis Methods to Insert Posttranslational Modifications into Recombinant Proteins
por: Harel, Omer, et al.
Publicado: (2022)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy
por: Buetti-Dinh, Antoine, et al.
Publicado: (2016)

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
por: Qiao, Meng, et al.
Publicado: (2020)

Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein
por: Kourentzi, Katerina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k98qn1puhunv5jl35d77euips1